Combinatorial approaches for novel cardiovascular drug discovery: a review of the literature. (3rd October 2022)

• Record Type: Journal Article
• Authors: Brogi, Simone; Tabanelli, Rita; Calderone, Vincenzo
• Is Part Of: Expert opinion on drug discovery. Volume 17:Number 10(2022)
• Page Start: 1111
• Page End: 1129
• Publication Date: 2022-10-03
• Subjects: Cardiovascular diseases (CVDs) -- combinatorial drug discovery -- fixed-dose combination (FDC) -- cardiovascular risk factors; 615.1
• DOI: 10.1080/17460441.2022.2104247
• Languages: English
• ISSNs: 1746-0441

Abstract

ABSTRACT: Introduction: In this article, authors report an inclusive discussion about the combinatorial approach for the treatment of cardiovascular diseases (CVDs) and for counteracting the cardiovascular risk factors. The mentioned strategy was demonstrated to be useful for improving the efficacy of pharmacological treatments and in CVDs showed superior efficacy with respect to the classical monotherapeutic approach. Areas covered: According to this topic, authors analyzed the combinatorial treatments that are available on the market, highlighting clinical studies that demonstrated the efficacy of combinatorial drug strategies to cure CVDs and related risk factors. Furthermore, the review gives an outlook on the future perspective of this therapeutic option, highlighting novel drug targets and disease models that could help the future cardiovascular drug discovery Expert opinion: The use of specifically designed and increasingly rational and effective drug combination therapies can therefore be considered the evolution of polypharmacy in cardiometabolic and CVDs. This approach can allow to intervene on multiple etiopathogenetic mechanisms of the disease or to act simultaneously on different pathologies/risk factors, using the combinations most suitable from a pharmacodynamic, pharmacokinetic, and toxicological perspective, thus finding the most appropriate therapeutic option.